Table 1.
Clinical characteristics of FGM-Japan participants
| Variables | |
|---|---|
| Age, years | 50.9 (15.2) |
| Male sex, % | 40.8 |
| Diabetes duration, years | 16.4 (11.9) |
| HbA1c, % | 7.6 (0.9) |
| GA, % | 21.8 (4.5) |
| Insulin treatment | |
| Daily total, U | 34.0 (15.4) |
| Basal, U | 11.5 (7.2) |
| Basal, % | 33.6 (14.0) |
| CGM metrics | |
| TAR | 28.3 (16.6) |
| TIR | 62.0 (13.9) |
| TBR | 9.7 (9.2) |
| ADRR | 41.2 (10.8) |
| %CV | 34.1 (6.0) |
| MAGE | 142.9 (35.1) |
| HBGI | 6.4 (4.3) |
| LBGI | 2.4 (2.4) |
| SD | 58.2 (14.5) |
| MODD | 76.8 (27.6) |
| Psychological | |
| PAID, points | 29.9 (20.0) |
| HFS-B, points | 20.5 (5.6) |
| HFS-W, points | 14.9 (10.4) |
Mean (SD, standard deviation) or %
GA glycated albumin, CGM continuous glucose monitoring, TAR time above range, TIR time in range, TBR time below range, ADRR average daily risk range, CV coefficient of variation, MAGE mean amplitude of glycemic excursion, HBGI high blood glucose index, LBGI low blood glucose index, SD standard deviation, MODD mean daily difference for inter-day variation, PAID problem areas in diabetes, HFS-B hypoglycemia fear survey-behavior, and HFS-W hypoglycemia fear survey-worry